Navigation Links
Hayes, Inc. Releases Guide to BRCA1 and BRCA2 Genetic Testing
Date:5/14/2010

Inappropriate referrals for BRCA1/2 testing drives costs and creates undue anxiety for women.

(PRWEB) May 14, 2010 -- A guide to BRCA1 and BRCA2 genetic testing has been released by Hayes, Inc. This comprehensive resource is designed to equip physicians and other healthcare professionals who are not trained in genetics with independent, evidence-based information to help them understand the complexities of BRCA1/2 gene testing.

According to the American Cancer Society, breast cancer is the most common cancer among American women, except for skin cancers. Women who carry a change in one of the breast cancer susceptibility genes, BRCA1 or BRCA2, have an increased risk of breast and ovarian cancer. Changes in the BRCA1/2 genes can occur in any racial or ethnic group, although in the U.S. they are found most often in Jewish women of Ashkenazi (Eastern Europe) origin. Increasing numbers of women are seeking information concerning their risk of developing breast or ovarian cancer, often with heightened anxiety that has been fueled by direct-to-consumer advertising and information in the social media.

“Knowledge of the genetic basis of a disease has the potential to revolutionize personal healthcare,” says Dr. Diane Allingham-Hawkins, Director, Hayes Genetic Test Evaluation Program. “Unfortunately, however, there is a great deal of misuse of expensive genetic tests due to a lack of understanding of the true clinical utility of these tests. In reality, only 5% of cases of breast or ovarian cancer are caused by these hereditary genetic changes.”

However, the combination of anxiety regarding cancer risk, direct-to-consumer advertising and publicity about the tests, and lack of physician knowledge in the field of genetics has led to inappropriate referrals for women seeing BRCA1 and BRCA2 genetic testing.

“We understand that some of the reasons for these inappropriate referrals are the physician’s concern about upsetting a patient by saying ‘no’ to her request, even though she doesn’t meet the guidelines for testing,” says Dr. Allingham-Hawkins. “However, test results will not provide useful information about cancer risk unless the woman meets these guidelines, and can lead to undue worry without providing any health benefit. In addition, the cost of these tests alone can be greater than $3500, with the recommended genetic counseling adding even more.”

Written in a style that can be understood by both the clinician and non-clinician, the Hayes Guide scrutinizes nearly 300 scientific and clinical publications to provide unbiased information and recommendations regarding BRCA1/2 testing in different patient populations. Included is an in-depth analysis describing each of these tests, with special attention focused on the clinical validity, analytical validity, clinical utility, cost, major payer coverage policies, genetic counseling recommendations, and what the future holds for genetic testing for hereditary breast and ovarian cancer. Generally, access to Hayes genetic test evaluations requires a password-protected subscription to the Hayes Knowledge Center. However, recognizing the importance of this information, Hayes is releasing this special volume for a one-time fee. Click here for more information.

Hayes, Inc. is an independent health technology research and consulting company dedicated to promoting better health outcomes through the use of evidence. The Hayes Genetic Test Evaluation (GTE) program cuts through the “genohype” to the scientific proof regarding the appropriate use of genetic and genomic tests in clinical practice. Currently, there are more than 2000 genetic and genomic tests for inherited and acquired disorders on the market in the United States. With an annual growth rate of 25%, this rapidly growing field has created challenges for healthcare professionals to respond quickly and appropriately to issues related to these tests. Hayes GTE conducts evidence-based assessments with clear, concise conclusions across a range of conditions and applications, including hereditary, cardiovascular, neurological, and developmental disorders, as well as oncology. www.hayesinc.com

Hayes, Inc.: Karen Matthias at 215-855-0615 or kmatthias(at)hayesinc(dot)com

###


Read the full story at http://www.prweb.com/releases/2010/05/prweb4000094.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Related medicine news :

1. Hayes, Inc. Technology Prognosis Team Tracks First-of-a-Kind Technologies
2. CerMedia Releases MarinePure High Surface Area Media for Aquatic Biofiltration
3. Premier Literacy Releases Version 12 of the Most Comprehensive Offering of Literacy Tools Available Today
4. Loadstar Sensors Releases LoadVUE-1000 Load Cell Software with Logging, Plotting and Alerting features
5. San Francisco Plastic Surgeon Releases Plastic Surgery Patient Recovery Blog
6. Wyatt Matas & Associates Releases White Paper on Future Home Healthcare Business Model
7. LeveragePoint Releases Complete Online Value Management Solution
8. “You Are Very Pretty”, Says Myeexpert As It Releases A Book, Poetic Expressions, Dedicated To The Beauty of Women.
9. STC Releases iPhone Application to Track Your Immunization Records – MyIR™
10. ASTRO releases SBRT for lung cancer report
11. American Human Development Project Releases 'A Century Apart,' Revealing Alarming Disparities in Well-Being Among U.S. Racial and Ethnic Groups
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... International Protein, ... nutritional and bodybuilding supplements, announced it attended the January ECRM trade show in Hilton ... and nutritional scientist who was determined to create a line of products that would ...
(Date:1/20/2017)... ... , ... “Mary Magdalene: Grace is Greater than Sin”: a unique and ... Christ firsthand. “Mary Magdalene: Grace is Greater than Sin” is the creation of published ... with countless women who had little knowledge of the female characters portrayed in the ...
(Date:1/20/2017)... Farmville, NC (PRWEB) , ... January 20, 2017 ... ... the vPEP ® Oscillating Positive Expiratory Pressure (OPEP) device, was featured in ... article by Doug Pursley, MEd, RRT-ACCS, FAARC, “Analysis of Three Oscillating Positive ...
(Date:1/20/2017)... ... 20, 2017 , ... “The Land of More and More”: a brilliant ... hunger, and shares the simple and achievable answer. “The Land of More and More” ... Fairview Missionary Church in Angola, Indiana where he works with the children’s ministry department. ...
(Date:1/19/2017)... ... 19, 2017 , ... Next week after January 20th, the fear for many ... that circumvent health needs of over 30 million. Many interviews with Dr. Carol Francis ... government public servants were suppose to prioritize. Interviews provided below. , Among ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... YORK , Jan. 19, 2017 This ... the current and future scenario of the global market. ... rising opioid consumption. Severe chronic constipation is a major ... to traditional laxatives. Hence, novel targeted therapy has been ... OIC sufferers, launch of targeted medicines, and growing awareness ...
(Date:1/19/2017)... 19, 2017  Stealth BioTherapeutics Inc. ( Stealth ), ... dysfunction, today announced new additions to its senior leadership ... Medical Officer, and Daniel Geffken as interim ... Jim Carr , Pharm.D. has been promoted to Chief ... to welcome Doug and Daniel to our management team, ...
(Date:1/19/2017)... January 19, 2017 According to a study ... is set to witness a CAGR of 6.5% during the forecast ... will continue to be the leading market for cryotherapy globally ... ... emphasizing on ensuring affordable and adequate supply of gas in order ...
Breaking Medicine Technology: